ZK 118182

Drug Profile

ZK 118182

Latest Information Update: 23 Jun 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Class Anti-ischaemics; Anticoagulants; Antihypertensives; Antiplatelets; Prostaglandins
  • Mechanism of Action Prostaglandin D agonists; Prostaglandin D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension; Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 15 Jun 2004 Discontinued - Preclinical for Hypertension in Germany (unspecified route)
  • 15 Jun 2004 Discontinued - Preclinical for Ischaemic heart disorders in Germany (unspecified route)
  • 15 Jun 2004 Discontinued - Preclinical for Thrombosis in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top